Copyright
©The Author(s) 2018.
World J Clin Oncol. Sep 14, 2018; 9(5): 110-118
Published online Sep 14, 2018. doi: 10.5306/wjco.v9.i5.110
Published online Sep 14, 2018. doi: 10.5306/wjco.v9.i5.110
Table 4 Selected (≥ 5%) grade 3-4 adverse events (NCI CTCAE version 4.0) n (%)
| SOC | PT | Irinotecan-naïve | Prior irinotecan | All |
| Any | 17 (56.7) | 15 (42.9) | 32 (49.2) | |
| Blood | Neutropenia | 4 (13.3) | 1 (2.9) | 5 (7.7) |
| Anemia | 3 (10.0) | 0 (0.0) | 3 (4.6) | |
| Thrombocytopenia | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Gastrointestinal | Nausea | 2 (6.7) | 0 (0.0) | 2 (3.1) |
| Vomiting | 1 (3.3) | 0 (0.0) | 1 (1.5) | |
| Mucositis | 3 (10.0) | 3 (8.6) | 6 (9.2) | |
| Diarrhea | 11 (36.7) | 9 (25.7) | 20 (30.8) | |
| Vascular | Hypertension | 2 (6.7) | 4 (11.4) | 6 (9.2) |
- Citation: Carola C, Ghiringhelli F, Kim S, André T, Barlet J, Bengrine-Lefevre L, Marijon H, Garcia-Larnicol ML, Borg C, Dainese L, Steuer N, Richa H, Benetkiewicz M, Larsen AK, Gramont A, Chibaudel B. FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. World J Clin Oncol 2018; 9(5): 110-118
- URL: https://www.wjgnet.com/2218-4333/full/v9/i5/110.htm
- DOI: https://dx.doi.org/10.5306/wjco.v9.i5.110